Get started
Author

André Luiz Cicilini

Observed names: A. Cicilini, A. L. Cicilini, A.L. Cicilini, Andre Luiz Cicilini, André Cicilini
Institution: AC Camargo Hospital
ORCID: 0000-0002-7263-9925
Observed ORCID: 0000-0002-7263-9925
OpenAlex ID: A5077628982
PARP Inhibitor Sensitivity in Tumors Harboring Non-BRCA Homologous Recombination Gene Alterations: Current Evidence Across Ovarian, Breast, Prostate, and Pancreatic Cancers
2026 · Elizabeth Santana dos Santos, André Luiz Cicilini, et al. · International Journal of Molecular Sciences · 5
Chronic Subdural Hematoma Spontaneous Resolution
2017 · Nícollas Rabelo, Vitor Pereira, et al. · Arquivos Brasileiros de Neurocirurgia Brazilian Neurosurgery · 4
PDF
Caso clínico: tromboembolismo pulmonar secundário em um paciente com COVID-19
2020 · André Luiz Cicilini, Alana Ferreira de Oliveira, et al. · Medicina (Ribeirão Preto) · 3
PDF
Níveis séricos de 25-hidroxivitamina D em idosos com Diabetes mellitus tipo 2 atendidos em um Hospital Universitário de Ribeirão Preto (SP).
2019 · André Luiz Cicilini, Malena Verona Singling, et al. · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · 1
Hereditary Breast Cancer in a Brazilian Referral Cohort: Germline Diversity and Genotype–Phenotype Associations
2026 · André Luiz Cicilini, Patrick Vinicius Cerqueira Batista, et al. · International Journal of Molecular Sciences
271P Retrospective analysis of patients with localized and metastatic duodenal adenocarcinoma: A real-world experience from a Brazilian cancer center
2026 · V.P. Basilio de Souza, A.L. Cicilini, et al. · Annals of Oncology
PDF
Impact of Race on Outcomes of Neoadjuvant Immunotherapy plus Chemotherapy for Triple-Negative Breast Cancer.
2026 · Patrick Vinicius Batista Cerqueira, Andre Luiz Cicilini, et al. · Brazilian Journal of Oncology
HER2 Expression in Tumors from Patients with Hereditary Breast Cancer: Biological Association or Random Overlap?
2026 · Letícia Coelho de Mattos, André Cicilini, et al. · Brazilian Journal of Oncology
Breast Cancer Associated with RAD51 Family Gene Mutations: Clinical, Histopathological, and Molecular Characterization
2026 · Letícia Coelho de Mattos, André Cicilini, et al. · Brazilian Journal of Oncology
Rewiring Treatment Pathways: How Molecular Profiling After CDK4/6 Inhibitor (CDK4/6i) Failure Shapes Future Therapy in Luminal HER2-Negative Breast Cancer
2026 · Letícia Coelho de Mattos, André Cicilini, et al. · Brazilian Journal of Oncology
Occult neoplasia in risk-reducing bilateral salpingo-oophorectomy: Pathological findings and clinical implications.
2026 · Lurick Soares, Bruna Tirapelli, et al. · Journal of Clinical Oncology
PDF
Does anatomical subsite matter in acral melanoma?: A cohort study of clinical and molecular features.
2026 · Luís Augusto Barbosa Franco Zörrer, André Luiz Cicilini, et al. · Journal of Clinical Oncology
PDF
Functional domain disruption to define the molecular and clinical spectrum of germline RAD51 family variants in hereditary breast cancer (BC).
2026 · André Luiz Cicilini, Sandrine Caputo, et al. · Journal of Clinical Oncology
Central nervous system metastases in hereditary breast cancer according to germline pathogenic variants: A real-world cohort study.
2026 · Eduarda Mirela Da Silva Montiel, André Luiz Cicilini, et al. · Journal of Clinical Oncology
PDF
Molecular profiling of male breast cancer in Brazil: Comprehensive genomic characterization of a Latin American cohort.
2026 · Elizabeth Santos, Patrick De Cerqueira, et al. · Journal of Clinical Oncology
Structural determinants compared with genetic ancestry and self-reported race in triple-negative breast cancer disparities: A multilevel analysis in an admixed population.
2026 · Patrick De Cerqueira, Rafael Canfield Brianese, et al. · Journal of Clinical Oncology
PDF
Abstract PS3-05-09: Approaches to Breast Cancer Risk Management in Ovarian Cancer (OC) Patients Harboring Germline BRCA1/2 Mutations (gBRCA1/2mut)
2026 · D. Guilherme de Albuquerque e Rodrigues de Sousa, L. Soares, et al. · Clinical Cancer Research
Abstract PS1-08-12: Rewiring Treatment Pathways: How Molecular Profiling After CDK4/6 Inhibitor (CDK4/6i) Failure Shapes Future Therapy in Luminal HER2-Negative Breast Cancer
2026 · L. Coelho de Mattos, A. Cicilini, et al. · Clinical Cancer Research
Abstract PS1-12-24: Optimal sequencing after progression with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer: a real-world analysis
2026 · V. Primo Basilio de Souza, N. Soldi, et al. · Clinical Cancer Research
Abstract PS3-02-23: Hereditary Breast Cancer (BC) in the Moderate-Risk Spectrum - Surgical Practices and Risk of Second Primary Tumors
2026 · A. L. Cicilini, J. C. Casali-da-Rocha, et al. · Clinical Cancer Research
Adjuvant Larotrectinib in a Resected Secretory Carcinoma-Like Lung Adenocarcinoma Harboring EML4-NTRK3 Fusion: Case Report
2025 · Vladmir Cláudio Cordeiro de Lima, Breno Jeha Araújo, et al. · JTO Clinical and Research Reports
PDF
Spontaneous Regression of Pulmonary Lymphomatoid Granulomatosis in a Patient with a Solid Tumor: A Case Report
2025 · André Luiz Cicilini, P. P. Lago, et al. · Clinical oncohematology
PDF
342P Decoding male breast cancer: A molecular perspective on diagnosis and treatment
2025 · P.V.B.D. Cerqueira, F.A.B. Campos, et al. · Annals of Oncology
425eP Identifying key predictors of pathological complete response to neoadjuvant chemotherapy in hereditary breast cancer: The role of pathogenic moderate-penetrance germline variants
2025 · A.L. Cicilini, J.C. Casali Da Rocha, et al. · Annals of Oncology
447eP Impact of HER2-low status on survival and tumor characteristics in hereditary breast cancer with pathogenic moderate penetrance germline variants
2025 · A.L. Cicilini, J.C. Casali Da Rocha, et al. · Annals of Oncology
PDF
Works count: 31
Citation count: 13
H-index: 3
I10-index:
Year
Topic
Type